Patent: 8,129,358
✉ Email this page to a colleague
Summary for Patent: 8,129,358
Title: | Substituted pyrazole and triazole compounds as KSP inhibitors |
Abstract: | Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof: ##STR00001## |
Inventor(s): | Xia; Yi (Palo Alto, CA), Mendenhall; Kris G. (Concord, CA), Barsanti; Paul A. (Pleasant Hill, CA), Walter; Annette O. (Mill Valley, CA), Duhl; David (Oakland, CA), Renhowe; Paul A. (Danville, CA) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 12/312,389 |
Patent Claims: | see list of patent claims |
Details for Patent 8,129,358
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2026-11-13 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2026-11-13 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2026-11-13 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2026-11-13 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2026-11-13 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2026-11-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |